COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D08KQK
|
|||
Drug Name |
PMID31244113-compound-2c
|
|||
Synonyms |
PMID31244113-C-2c
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Middle East Respiratory Syndrome (MERS) | Preclinical | [1] | Severe acute respiratory syndrome (SARS) | Preclinical | [1] |
Therapeutic Class |
Antiviral Agents
|
|||
Structure |
Download2D MOL |
Target | Top | |||
---|---|---|---|---|
Target(s) | MERS-CoV RNA-directed RNA polymerase (RdRp) | Target Info | Inhibitor | [1] |
Compounds 2c exhibits a promising inhibitory activity against MERS-Cov RdRp with EC50 of 0.5 microM. | ||||
SARS-CoV RNA-directed RNA polymerase (RdRp) | Target Info | Inhibitor | [1] | |
6',6'-Difluoroaristeromycin (2c) shows the strongest antiviral effect for SARS-CoV RdRp, with a 2.5 log reduction in infectious progeny titer in viral load reduction assay. |
References | Top | |||
---|---|---|---|---|
1 | Design, Synthesis, and Anti-RNA Virus Activity of 6'-Fluorinated-Aristeromycin Analogues. J Med Chem. 2019 Jul 11;62(13):6346-6362. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.